Seres Therapeutics (MCRB) Short Interest Ratio & Short Volume $0.77 +0.03 (+4.41%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$0.77 +0.00 (+0.34%) As of 09:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Seres Therapeutics Short Interest DataSeres Therapeutics (MCRB) has a short interest of 20.44 million shares. This marks a 4.23% increase in short interest from the previous month. The short interest ratio (days to cover) is 7.6, indicating that it would take 7.6 days of the average trading volume of 1.68 million shares to cover all short positions.Current Short Interest20,440,000 sharesPrevious Short Interest19,610,000 sharesChange Vs. Previous Month+4.23%Dollar Volume Sold Short$16.99 millionShort Interest Ratio7.6 Days to CoverLast Record DateDecember 31, 2024Outstanding Shares170,740,000 sharesPercentage of Shares Shorted11.97%Today's Trading Volume819,773 sharesAverage Trading Volume1,684,592 sharesToday's Volume Vs. Average49% Short Selling Seres Therapeutics? Sign up to receive the latest short interest report for Seres Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMCRB Short Interest Over TimeMCRB Days to Cover Over TimeMCRB Percentage of Float Shorted Over Time Seres Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 12/31/202420,440,000 shares $16.99 million +4.2%N/A7.6 $0.83 12/15/202419,610,000 shares $17.23 million +12.8%N/A5.6 $0.88 11/30/202417,380,000 shares $17.03 million +7.0%N/A4.5 $0.98 11/15/202416,240,000 shares $8.93 million -9.0%N/A4 $0.55 10/31/202417,850,000 shares $14.63 million -1.1%N/A5 $0.82 10/15/202418,050,000 shares $14.72 million -3.3%N/A4.7 $0.82 9/30/202418,660,000 shares $17.65 million +8.4%N/A4.4 $0.95 9/15/202417,220,000 shares $17.21 million +8.0%N/A4.5 $1.00 8/31/202415,940,000 shares $12.76 million -4.8%N/A4.2 $0.80 8/15/202416,750,000 shares $14.82 million +2.4%N/A4.3 $0.89 Get the Latest News and Ratings for MCRB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Seres Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/31/202416,360,000 shares $21.92 million -3.8%N/A3.7 $1.34 7/15/202417,000,000 shares $20.23 million -17.8%N/A3.4 $1.19 6/30/202420,690,000 shares $14.98 million -9.5%N/A4.3 $0.72 6/15/202422,850,000 shares $16.18 million +1.1%N/A4.9 $0.71 5/31/202422,600,000 shares $22.60 million -0.6%N/A4.5 $1.00 5/15/202422,740,000 shares $21.78 million +6.0%N/A4.7 $0.96 4/30/202421,460,000 shares $21.26 million +21.7%N/A4.6 $0.99 4/15/202417,630,000 shares $10.89 million -6.2%N/A4.4 $0.62 3/31/202418,800,000 shares $14.55 million +2.2%N/A4 $0.77 3/15/202418,400,000 shares $14.46 million +14.3%N/A3.9 $0.79 2/29/202416,100,000 shares $18.35 million +3.3%N/A3.3 $1.14 2/15/202415,590,000 shares $17.46 million No ChangeN/A3.5 $1.12 1/31/202415,590,000 shares $17.62 million -11.2%N/A3.4 $1.13 1/15/202417,550,000 shares $21.06 million +7.8%N/A3.3 $1.20 12/31/202316,280,000 shares $22.79 million -21.8%N/A3.3 $1.40 12/15/202320,810,000 shares $20.66 million -0.7%N/A5 $0.99 11/30/202320,950,000 shares $21.79 million -10.4%N/A6 $1.04 11/15/202323,370,000 shares $28.04 million +1.2%N/A6.8 $1.20 10/31/202323,100,000 shares $35.34 million +1.1%N/A7.3 $1.53 10/15/202322,850,000 shares $34.28 million +7.9%N/A9.3 $1.50 9/30/202321,170,000 shares $50.38 million +3.8%N/A10 $2.38 9/15/202320,400,000 shares $58.34 million +0.8%N/A9.6 $2.86 8/31/202320,230,000 shares $69.79 million -13.4%N/A8.5 $3.45 8/15/202323,350,000 shares $87.56 million +3.6%N/A9.3 $3.75 7/31/202322,550,000 shares $108.47 million +1.7%N/A8.5 $4.81 7/15/202322,180,000 shares $100.25 million -2.9%N/A6.4 $4.52 6/30/202322,830,000 shares $109.36 million +25.0%N/A6.3 $4.79 6/15/202318,260,000 shares $104.45 million +17.7%N/A5.2 $5.72 5/31/202315,520,000 shares $76.82 million +3.4%N/A5.1 $4.95 5/15/202315,010,000 shares $80.00 million +23.2%N/A5.4 $5.33Ignore every stock… (Ad)Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%We put together this handy gold guide for you (no cost) so you know what to look for 4/30/202312,180,000 shares $59.38 million +36.1%N/A4.9 $4.88 4/15/20238,950,000 shares $52.45 million +3.4%N/A6.2 $5.86 3/31/20238,660,000 shares $49.10 million -7.0%N/A8.4 $5.67 3/15/20239,310,000 shares $54.00 million +19.1%N/A10.5 $5.80 2/28/20237,820,000 shares $39.49 million +8.9%N/A9.9 $5.05 2/15/20237,180,000 shares $36.83 million +9.6%N/A9.9 $5.13 1/31/20236,550,000 shares $35.83 million -0.3%N/A8.9 $5.47 1/15/20236,570,000 shares $36.00 million -3.5%N/A8.2 $5.48 12/30/20226,810,000 shares $38.14 million +43.7%N/A8.5 $5.60 12/15/20224,740,000 shares $27.68 million +11.3%N/A5.7 $5.84 11/30/20224,260,000 shares $27.69 million -1.6%N/A4.4 $6.50 11/15/20224,330,000 shares $30.92 million -9.2%N/A4.4 $7.14 10/31/20224,770,000 shares $42.26 million -3.4%N/A4.8 $8.86 10/15/20224,940,000 shares $33.94 million +0.2%N/A4.9 $6.87 9/30/20224,930,000 shares $31.65 million +45.9%N/A4.7 $6.42 9/15/20223,380,000 shares $24.23 million -1.2%N/A3 $7.17 8/31/20223,420,000 shares $17.58 million +5.2%N/A3 $5.14 8/15/20223,250,000 shares $18.49 million -12.6%3.8%2.8 $5.69 7/31/20223,720,000 shares $15.29 million +4.8%4.6%3 $4.11 7/15/20223,550,000 shares $12.82 million -5.6%4.4%3.1 $3.61 6/30/20223,760,000 shares $12.90 million -25.0%4.6%3.5 $3.43 6/15/20225,010,000 shares $14.13 million +5.7%7.2%5.1 $2.82 5/31/20224,740,000 shares $14.69 million -5.4%6.8%5.6 $3.10 5/15/20225,010,000 shares $18.99 million +0.4%7.2%6.5 $3.79 4/30/20224,990,000 shares $23.60 million +8.2%7.2%6.7 $4.73 4/15/20224,610,000 shares $28.03 million -0.4%6.6%6.1 $6.08 3/31/20224,630,000 shares $32.97 million -14.9%6.7%5.8 $7.12 3/15/20225,440,000 shares $37.37 million -0.4%7.8%6.2 $6.87 2/28/20225,460,000 shares $43.68 million -0.2%7.8%4.3 $8.00 2/15/20225,470,000 shares $46.17 million -1.1%7.9%3.6 $8.44 1/31/20225,530,000 shares $46.12 million -14.8%8.0%3 $8.34 1/15/20226,490,000 shares $52.18 million +9.8%9.3%3.5 $8.04 12/31/20215,910,000 shares $49.23 million -34.3%8.5%3.2 $8.33 12/15/20218,990,000 shares $78.48 million +7.8%12.9%4.7 $8.73 11/30/20218,340,000 shares $89.74 million -6.2%12.0%4.3 $10.76 11/15/20218,890,000 shares $69.43 million +2.0%12.8%4.8 $7.81 10/29/20218,720,000 shares $53.02 million +7.0%12.6%5.5 $6.08 10/15/20218,150,000 shares $51.43 million -10.4%11.8%4.7 $6.31 9/30/20219,100,000 shares $63.34 million +70.1%13.1%4.4 $6.96 9/15/20215,350,000 shares $33.97 million -15.9%7.7%2.5 $6.35 8/31/20216,360,000 shares $40.77 million -9.0%9.2%3.6 $6.41 8/13/20216,990,000 shares $46.48 million +6.1%10.2%4.7 $6.65 7/30/20216,590,000 shares $46.79 million +6.6%9.6%4.5 $7.10 7/15/20216,180,000 shares $125.27 million -2.1%9.0%5.1 $20.27 6/30/20216,310,000 shares $150.49 million -7.5%9.2%7.8 $23.85 6/15/20216,820,000 shares $136.81 million -1.6%9.9%8.7 $20.06 5/28/20216,930,000 shares $146.29 million -2.5%10.1%8.8 $21.11 5/14/20217,110,000 shares $146.89 million -9.5%10.3%7.7 $20.66 4/30/20217,860,000 shares $166.47 million -1.0%11.4%8.1 $21.18 4/15/20217,940,000 shares $163.96 million +1.2%11.6%8.1 $20.65Ignore every stock… (Ad)Stocks have been on a tear in 2024… And there’s plenty of great opportunities out there. But one expert says you should forget about EVERY stock for a moment and focus on an even bigger opportunity. The current GOLD supercycle You see, stocks are a dime a dozen for the most part… And, fortunately, they go up more than they go down. But every few decades, precious metals have a systematic supercycle that tends to dwarf the potential of just about anything else. The last time things aligned like this on gold it surged 536%We put together this handy gold guide for you (no cost) so you know what to look for 3/31/20217,850,000 shares $152.53 million +8.6%11.5%7.4 $19.43 3/15/20217,230,000 shares $154.51 million +10.2%10.6%6.2 $21.37 2/26/20216,560,000 shares $123.26 million +10.1%9.6%5.8 $18.79 2/12/20215,960,000 shares $155.32 million -14.2%8.7%5.5 $26.06 1/29/20216,950,000 shares $166.17 million -5.2%10.2%6.6 $23.91 1/15/20217,330,000 shares $195.78 million +3.4%10.8%7.3 $26.71 12/31/20207,090,000 shares $186.11 million +56.2%10.4%7.6 $26.25 12/15/20204,540,000 shares $112.64 million -6.8%6.7%5.3 $24.81 11/30/20204,870,000 shares $141.28 million -3.9%7.3%6.4 $29.01 11/15/20205,070,000 shares $174.71 million +6.5%8.4%6.9 $34.46 10/30/20204,760,000 shares $142.13 million -7.9%8.2%4 $29.86 10/15/20205,170,000 shares $167.66 million +12.6%9.0%1.8 $32.43 9/30/20204,590,000 shares $129.94 million No Change7.9%1.6 $28.31 9/15/20204,590,000 shares $125.40 million -12.4%7.9%1.6 $27.32 8/31/20205,240,000 shares $138.81 million -25.5%9.1%1.8 $26.49 8/14/20207,030,000 shares $191.64 million -21.2%13.2%2.5 $27.26 7/31/20208,920,000 shares $33.36 million +16.3%19.6%3.9 $3.74 7/15/20207,670,000 shares $31.68 million +3.1%17.7%11.8 $4.13 6/30/20207,440,000 shares $34.74 million +6.1%17.1%13.2 $4.67 6/15/20207,010,000 shares $30.70 million +4.0%16.1%16 $4.38 5/29/20206,740,000 shares $37.00 million +8.7%15.7%16.9 $5.49 5/15/20206,200,000 shares $28.52 million +10.9%14.5%16.8 $4.60 4/30/20205,590,000 shares $21.86 million +9.6%13.1%17.4 $3.91 4/15/20205,100,000 shares $18.87 million +6.7%12.2%19.3 $3.70 3/31/20204,780,000 shares $17.35 million -7.9%11.4%18.8 $3.63 3/13/20205,187,600 shares $17.59 million +4.8%12.5%19.3 $3.39 2/28/20204,950,000 shares $16.83 million +2.3%12.0%22.9 $3.40 2/14/20204,840,000 shares $14.62 million +1.9%11.9%22.9 $3.02 1/31/20204,750,000 shares $16.96 million +3.3%11.6%22.7 $3.57 MCRB Short Interest - Frequently Asked Questions What is Seres Therapeutics' current short interest? Short interest is the volume of Seres Therapeutics shares that have been sold short but have not yet been covered or closed out. As of December 31st, investors have sold 20,440,000 shares of MCRB short. Learn More on Seres Therapeutics' current short interest. What is a good short interest ratio for Seres Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MCRB shares currently have a short interest ratio of 8.0. Learn More on Seres Therapeutics's short interest ratio. Which institutional investors are shorting Seres Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Seres Therapeutics: Wolverine Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Seres Therapeutics' short interest increasing or decreasing? Seres Therapeutics saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 20,440,000 shares, an increase of 4.2% from the previous total of 19,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Seres Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Seres Therapeutics: Kura Oncology, Inc. (16.00%), CARGO Therapeutics, Inc. (18.87%), Humacyte, Inc. (28.38%), Pharvaris (0.96%), Annexon, Inc. (8.42%), Keros Therapeutics, Inc. (10.64%), Mereo BioPharma Group plc (5.18%), Rapport Therapeutics (10.13%), Entrada Therapeutics, Inc. (8.41%), Ginkgo Bioworks Holdings, Inc. (20.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.83 billion), Charter Communications, Inc. ($3.77 billion), Reddit, Inc. ($2.98 billion), The Kroger Co. ($2.97 billion), International Paper ($2.64 billion), SoFi Technologies, Inc. ($1.99 billion), Rivian Automotive, Inc. ($1.93 billion), Onsemi ($1.81 billion), SoundHound AI, Inc. ($1.59 billion), and Moderna, Inc. ($1.57 billion). View all of the most shorted stocks. What does it mean to sell short Seres Therapeutics stock? Short selling MCRB is an investing strategy that aims to generate trading profit from Seres Therapeutics as its price is falling. MCRB shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Seres Therapeutics? A short squeeze for Seres Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MCRB, which in turn drives the price of the stock up even further. How often is Seres Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MCRB, twice per month. The most recent reporting period available is December, 31 2024. More Short Interest Resources from MarketBeat Related Companies Kura Oncology Short Squeeze CARGO Therapeutics Short Squeeze Humacyte Short Squeeze Pharvaris Short Squeeze Annexon Short Squeeze Keros Therapeutics Short Squeeze Mereo BioPharma Group Short Squeeze Rapport Therapeutics Short Squeeze Entrada Therapeutics Short Squeeze Ginkgo Bioworks Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MCRB) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
